Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR®, ArmoredCAR®, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan